ulixacaltamide
Phase 3Small molecule
ulixacaltamide is one of 12 small molecule programs targeting Essential Tremor. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
ulixacaltamide
PPraxis Precision Medicines
Phase 3
AGN-151607-DP
AbbViePhase 2
BP1.4979
BBioprojet
Phase 2
Inderal
WWyeth-Lederle Vaccines
Preclinical
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ulixacaltamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPraxis Precision Medicines